NCT04818853View on ClinicalTrials.gov

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

CompletedOBSERVATIONAL
Enrollment

219

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

July 20, 2022

Study Completion Date

January 13, 2023

Conditions
Covid19AspergillosisFungal Infection
Interventions
OTHER

Observation to monitor patients for these infections

We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.

Trial Locations (1)

35233

The University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT04818853 - COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI) | Biotech Hunter | Biotech Hunter